Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N-acetylcysteine for paracetamol overdose—the PP100–01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial by ,
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Randomised open label exploratory, safety and tolerability study
with calmangafodipir in patients treated with the 12-h regimen of
N-acetylcysteine for paracetamol overdose—the PP100–01 for
Overdose of Paracetamol (POP) trial: study protocol for a
randomised controlled trial
Citation for published version:
The POP Trial Investigators 2019, 'Randomised open label exploratory, safety and tolerability study with
calmangafodipir in patients treated with the 12-h regimen of N-acetylcysteine for paracetamol
overdose—the PP100–01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised
controlled trial' Trials, vol. 20, no. 1. DOI: 10.1186/s13063-018-3134-1
Digital Object Identifier (DOI):
10.1186/s13063-018-3134-1
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Trials
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
STUDY PROTOCOL Open Access
Randomised open label exploratory, safety
and tolerability study with calmangafodipir
in patients treated with the 12-h regimen
of N-acetylcysteine for paracetamol
overdose—the PP100–01 for Overdose of
Paracetamol (POP) trial: study protocol for a
randomised controlled trial
The POP Trial Investigators and James Dear*
Abstract
Background: Paracetamol (acetaminophen) overdose (POD) is the commonest cause of acute liver failure in
Europe and North America. Current treatment involves the use of the antidote N-acetylcysteine (NAC) in patients
deemed at risk of liver damage. This regimen was introduced in the 1970s and has remained largely unchanged
even though the initial NAC infusion is frequently associated with adverse reactions, in particular nausea, vomiting,
and anaphylactoid reactions. NAC has reduced efficacy for preventing liver injury in those patients who present
later after overdose. We designed a randomised study investigating the safety and tolerability of a superoxide
dismutase (SOD) mimetic, calmangafodipir (PP100–01), co-treatment with a 12-h NAC regimen compared with NAC
treatment alone in patients with POD.
Methods/design: We have designed an open-label, randomised, exploratory, rising dose design, NAC-controlled,
phase 1 safety and tolerability study in patients treated with NAC for POD. A total of 24 patients will be assigned
into one of three dosing cohorts of eight patients (n = 6 for PP100–01 and NAC; n = 2 for NAC alone). The doses of
PP100–01 are 2, 5, and 10 μmol/kg. The primary outcome is the safety and tolerability of PP100–01 when co-
administered with a 12-h NAC regimen compared with NAC treatment alone. Furthermore, the study will explore if
PP100–01 has potential efficacy for the treatment of paracetamol-induced liver injury by measurement of
conventional clinical and exploratory biomarkers.
Discussion: The aim of the study is to test the safety and tolerability of a SOD mimetic, PP100–01, in combination
with a 12-h NAC regimen in patients presenting within 24 h of POD. This study will provide valuable data regarding
the incidence of adverse events caused by the 12-h NAC plus PP100–01 regimen and may provide evidence of
PP100–01 efficacy in the treatment of paracetamol-induced liver injury.
Trial registration: EudraCT, 2017–000246-21; ClinicalTrials.gov, NCT03177395. Registered on 6 June 2017.
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Background
Paracetamol/acetaminophen (N-acetyl-p-aminophenol
(APAP)) is the most common agent taken as an over-
dose in the UK. APAP is ingested by approximately 40%
of patients admitted to hospital with self-harm. Annu-
ally, overdose directly leads to around 100,000 hospital
attendances in the UK with around half of these patients
being admitted to hospital for emergency antidote treat-
ment [1]. APAP is responsible for the deaths of around
100–150 people per year in the UK [2]. In the USA,
APAP overdose accounts for more than 56,000 hospital
attendances and around 450 deaths due to acute liver
failure each year [3].
In paracetamol overdose (POD), the normal APAP de-
toxification pathways (sulphation and glucuronidation)
are overwhelmed, leading to the formation of the react-
ive intermediate metabolite,
N-acetyl-p-benzoquinoneimine (NAPQI), which binds
covalently to liver proteins resulting in cell death. Ex-
perimental animal data demonstrate that APAP-induced
toxicity occurs in two phases: an initial metabolic phase
followed by an oxidative phase. In human patients, the
metabolic phase is predominantly during the first 8 h
(0–8 h) with the oxidative phase dominating thereafter
(> 8 h). During the metabolic phase, APAP metabolites
are conjugated and excreted via the kidneys. In the oxi-
dative phase the glutathione (GSH) stores are depleted
and the reactive metabolite NAPQI binds to liver pro-
teins with increased oxidative stress and, ultimately, loss
of mitochondrial membrane potential and subsequent
cell death [4]. Oxidative stress can directly trigger mito-
chondrial membrane permeability with pore opening
and collapse of the mitochondrial membrane potential.
The toxicity of reactive oxygen and reactive nitrogen
species is potentiated by the fact that mitochondrial
GSH levels are severely depleted during the APAP me-
tabolism, which leaves these organelles highly vulnerable
to injury.
In humans, APAP-induced liver injury is usually
asymptomatic in its early stages. Nausea, vomiting, and
abdominal pain are common soon after overdose but are
not specific for liver injury. As toxicity progresses, the
patient may experience pain in the region of the liver. In
severe poisoning, hepatic encephalopathy and acute kid-
ney injury can occur and these features are used to iden-
tify patients that need liver transplantation to avoid
death. Acetylcysteine (N-acetylcysteine (NAC)) was de-
veloped as an antidote for APAP poisoning in the 1970s
and remains the mainstay for the prevention of
APAP-induced hepatotoxicity. It is metabolised in the
liver to the glutathione substrate cysteine. Glutathione is
required for the detoxification of NAPQI to produce less
toxic cysteine and mercapturic acid conjugates. POD pa-
tients in the UK receive an intravenous 21-h regimen of
150 mg/kg over 1 h, then 50mg/kg over 4 h, then 100
mg/kg over 16 h (total dose 300mg/kg) [5]. Although ef-
fective at preventing APAP-induced hepatotoxicity when
used within 8 h of overdose, this regimen was largely
empirical and not based on robust initial dose-ranging
studies. The 21-h NAC regime is associated with the fol-
lowing challenges. i) Adverse drug reactions, since it is
commonly associated with unpleasant and occasionally
severe dose-related adverse drug reactions [6]. Nausea/
vomiting occurs in more than half of recipients and ana-
phylactoid reactions in about a third. While cutaneous
features are most common (flushing, itching), systemic
effects occur in up to 5% of recipients. Severe reactions
result in treatment interruption, treatment refusal, and
extended hospital stays. ii) Medication error, since the
regimen is complex, involving three separate
weight-related infusions over different time frames. As a
result, there is a high risk of medication error and deaths
have been reported. iii) Prolonged duration, since the re-
gime is time consuming, taking at least 21 h, leading to
significant hospital bed occupancy (around 47,000 bed
days per year in England) [7].
To address these shortcomings of the standard NAC
regimen, a shorter 12-h intravenous regimen has been
developed (the ‘SNAP’ regimen). In this 12-h NAC regi-
men, the initial loading dose (NAC 100mg/kg in 200
mL) is given over 2 h, followed by a second dose (200
mg/kg in 1000 mL) infused over 10 h. This 12-h NAC
regimen has been demonstrated to be effective in redu-
cing the incidence of vomiting and anaphylactoid reac-
tions compared with the standard intravenous
acetylcysteine schedule [8]. The shorter duration of acet-
ylcysteine infusion offers simpler administration, a prob-
able reduction in administration errors, and potentially a
substantial decrease in the length of hospital stay. Since
September 2015, this 12-h NAC regimen has been deliv-
ered as standard clinical care at the Royal Infirmary of
Edinburgh, UK.
Mangafodipir was originally developed as a magnetic
resonance imaging (MRI) contrast agent and approved
for that indication by the US Food and Drug Adminis-
tration (FDA) and the European Medicines Agency
(EMA). Approximately 240,000 patients have received
single doses of mangafodipir with no significant safety
concerns. Mangafodipir has been demonstrated to pre-
vent APAP-induced liver injury in mice by acting as a
superoxidase dismutase (SOD) mimetic. In mice, this
protection is at a time point when NAC is no longer ac-
tive, presumably corresponding with the oxidative phase
of injury [9]. Therefore, mangafodipir may provide pro-
tection against POD in humans at a time when NAC
treatment is less effective.
Calmangafodipir (Ca4Mn(DPDP)5) is a unique chem-
ical species derived from mangafodipir, where 80% of the
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manganese in mangafodipir has been replaced with cal-
cium. Based on the similarities between calmangafodipir
and mangafodipir, it is anticipated that calmangafodipir
would also exhibit SOD-dependent pharmacologic ac-
tions similar to those of mangafodipir [10]. Calmangafo-
dipir (referred to in this protocol as PP100–01) has been
studied in a phase 2 safety and efficacy study (PLIANT)
of chemotherapy-induced peripheral neuropathy in pa-
tients with advanced metastatic colorectal cancer. In the
PLIANT study, calmangafodipir was well tolerated
across all three doses of 2, 5, and 10 μmol/kg [11]. Cal-
mangafodipir, at a dose of 5 μmol/kg, prevented the de-
velopment of chemotherapy-induced peripheral
neuropathy without apparent influence on tumour
outcomes.
To support clinical trials with calmangafodipir, this
compound has undergone standard toxicity testing con-
sisting of repeat dose studies of up to 6months duration
in rats and 9months duration in dogs with intravenous
dosing once every fortnight. Calmangafodipir showed
good tolerability in both species with a no observed ad-
verse effect level in the 6- and 9-month studies of 144-
and 30-fold, respectively, above the highest clinical dose
of 10 μmol/kg. Exposures obtained in terms of whole
blood manganese levels as well as plasma Cmax and area
under the curve (AUC) of the main metabolite PLED
relative to the corresponding clinical exposures at
10 μmol/kg gave additional reassurance of the good tol-
erability of calmangafodipir.
When investigated in the Ames Salmonella assay and
in a micronucleus assay in human lymphocytes, calman-
gafodipir showed no relevant genotoxic activity.
Investigations on fertility and early embryonic devel-
opment in the rat with mangafodipir, a compound with
similar circulating metabolites to that of calmangafodi-
pir, revealed no negative effects up to the highest dose
(100 μmol/kg) investigated [12]. However, in standard
testing for embryofetal development toxicity, skeletal ab-
normalities have been observed in the rat at intravenous
doses from 10 μmol/kg while in the rabbit incomplete
ossification was seen after 20 μmol/kg [12]. These effects
are related to manganese exposure since MnCl2 was
shown in the rat to induce the same skeletal abnormal-
ities as mangafodipir at equivalent molar doses. No ad-
verse effects were observed when pregnant rats were
administered mangafodipir up to day 7 of gestation, i.e.
prior to major organogenesis taking place in this species.
The objective of the PP100–01 for Overdose of Para-
cetamol (POP) trial is to develop a therapeutic regimen
for POD where a 12-h NAC infusion protocol is com-
bined with PP100–01 to evaluate safety and tolerability
and to provide information regarding the potential effi-
cacy of this combination for preventing liver injury. The
primary objective is to assess the adverse events (AEs)
and serious adverse events (SAEs) associated with
PP100–01 co-treatment with the 12-h NAC treatment
regime in patients with POD. A secondary study object-
ive is to determine if there is evidence of PP100–01 hav-
ing efficacy by measurement of clinical and exploratory
biomarkers. The exploratory biomarkers (microRNA-122
(miR-122), keratin-18 (K18), and glutamate dehydrogen-
ase (GLDH)) are supported for use in the assessment of
drug-induced liver injury in clinical trials, both by the
EMA and the FDA. As they have been demonstrated to
have enhanced sensitivity for identifying liver injury in
the context of APAP overdose, their measurement may
allow sub-clinical liver injury to be quantified [13].
Methods
Ethical and regulatory approval
This study, EudraCT number 2017–000246-21 and Clin-
icalTrials.gov identifier NCT03177395, is funded by the
Sponsor, PledPharma AB, Stockholm, Sweden, and was
approved by the UK medicines regulator, Medicines and
Healthcare products Regulatory Agency (MHRA; 25
April 2017), and West of Scotland Research Ethics Com-
mittee 1, Glasgow, UK (approval 11 April 2017). The
trial was designed by collaborators at the Clinical Toxi-
cology unit in the Royal Infirmary of Edinburgh and the
Edinburgh Clinical Trials Unit. The protocol was de-
signed in accordance with the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
(Additional file 1). The trial overview is available as a
SPIRIT figure (Fig. 1).
Rationale for study drugs and doses
Acetylcysteine treatment
After a single acute APAP overdose with a known time
of drug ingestion, in the UK a nomogram is used to
identify patients who require NAC treatment based on
the plasma APAP concentration and time from ingestion
(Fig. 2). Patients with timed plasma concentrations
above the treatment line receive treatment with the full
course of intravenous NAC. Those patients below the
treatment line receive no NAC treatment and can be
considered for medical discharge.
In patients presenting to hospital up to 8 h after a sin-
gle overdose, the need for NAC treatment can be
assessed once the plasma APAP concentration is known.
In patients presenting later than 8 h (as well as staggered
POD), NAC treatment is initiated if the patient reports
ingesting a potentially toxic dose (150 mg/kg body
weight). Once blood results are available NAC treatment
can be stopped or continued.
In this clinical trial NAC is to be delivered by the 12-h
SNAP regimen because this regimen is associated with
few adverse reactions. This superior safety profile (com-
pared to the 21-h regimen) will aid the identification of
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safety signals directly relating to PP100–01 and NAC
co-treatment.
PP100–01 treatment
With regards to the choice of dose, in the phase II PLI-
ANT trial in patients with advanced metastatic colorec-
tal cancer, calmangafodipir (PledOx®; 2, 5, or 10 μmol/
kg) was infused intravenously as a pre-treatment single
dose over approximately 5 min. PledOx® was well toler-
ated across all three doses. There were no differences
between PledOx®-treated arms and placebo in terms of
AEs [11]. The mechanism of action of calmangafodipir
in preventing chemotherapy-induced peripheral neur-
opathy is comparable to its proposed mechanism in
APAP toxicity, namely acting as a SOD mimetic, which
prevents cellular oxidative stress. Although the target
organ is different, in this study the doses of PP100–01
will be the same as that in PLIANT.
Study design
The study is an open-label, randomised, exploratory, ris-
ing dose design, NAC-controlled, phase 1 safety and tol-
erability study in patients treated with NAC for POD.
Consent will be obtained prior to any study-specific pro-
cedures being carried out by delegated trained clinical
staff and recorded on a consent form in triplicate, with
one copy given to the participant, one placed in the In-
vestigator Site File (ISF), and one placed in the hospital
notes. Entry into the study is dependent on the patient’s
blood results confirming the need for NAC. A total of
24 patients will be assigned into one of three dosing co-
horts of eight patients (n = 6 for NAC plus PP100–01; n
Fig. 1 SPIRIT figure for the POP Trial. *If AEs/SAEs identified that require a full physical examination to be completed (X), NAC continued as per
TOXBASE (12 h ± 30 min); 2- and 2.5-h assessments should be performed ± 15 min of the time point. PP100–01 treatment should be ± 10 min of
the time point. 10- and 20-h assessments should be performed ± 30min of the time point. ALP alkaline phosphatase, ALT alanine transaminase,
APAP paracetamol/acetaminophen, BP blood pressure, ECG electrocardiogram, Hb haemoglobin, INR international normalised ratio, MCV mean
cell volume, NAC N-acetylcysteine, P Pulse, WBC white blood cell
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= 2 for NAC alone). Patients that have signed the in-
formed consent form will be treated with NAC plus one
of a rising series of doses of PP100–01. Each PP100–01
treatment dosing cohort will have eight patients, six ran-
domised to NAC plus PP100–01 and two randomised to
NAC alone. The doses of PP100–01 are 2, 5, and
10 μmol/kg.
Identifying patients
Treating clinicians at the Emergency Department of the
Royal Infirmary of Edinburgh will identify potentially eli-
gible patients. A trained member of staff will then assess
the patient for study eligibility.
Inclusion criteria:
1. Any patient with capacity admitted to hospital
within 24 h of either a single acute POD or more
than one dose of APAP (staggered) and deemed to
require treatment with NAC.
2. Provision of written informed consent
3. Males and females of at least 16 years of age
Exclusion criteria:
1. Patients that do not have the capacity to consent to
participate in the study
2. Patients detained under the Mental Health Act or
deemed unfit by the Investigator to participate due
to mental health
3. Patients with known permanent cognitive
impairment
4. Patients who are pregnant or nursing
5. Patients who have previously participated in the
study
6. Unreliable history of POD
7. Patients presenting more than 24 h after POD
8. Patients who take anticoagulants (e.g. warfarin)
therapeutically or have taken an overdose of
anticoagulants
9. Patients who, in the opinion of the responsible
clinician/nurse, are unlikely to complete the full
course of NAC, e.g. expressing wish to self-
discharge
10. Prisoners
11. Non-English-speaking patients (study information
material will only be produced in English in view of
the known and stable demographic of the
Edinburgh self-harm population)
Fig. 2 The paracetamol treatment nomogram used in the United Kingdom. After a single acute overdose, the patient’s plasma/serum
paracetamol concentration is plotted on the graph using the time from overdose to blood draw. If above the treatment line the patient receives
acetylcysteine treatment at a dose of 300 mg/kg body weight
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Blood samples
As part of routine clinical care all patients presenting to
hospital following a POD have the following blood tests
on arrival to hospital or 4 h after overdose (whichever is
the longer time).
 APAP concentration
 Urea, sodium, potassium, and creatinine
 Liver function tests (LFTs): alanine transaminase
(ALT) activity, bilirubin, and alkaline phosphatase
(ALP) activity.
 Clotting screen: international normalised ratio (INR)
and prothrombin time (PT)
 Haemoglobin, white blood cells (WBC), and mean
cell volume (MCV)
The clinical decision to treat a patient with NAC is
largely based on their APAP concentration in combin-
ation with their ALT activity and INR.
As part of routine clinical care, blood sampling will be
taken to measure the above analytes at 10 h and 20 h
after starting NAC (Fig. 3).
As part of a study examining exploratory biomarkers
(miR-122, K18, and GLDH), a study-specific blood sam-
ple will be collected (10 mL split over serum and
plasma) immediately prior to administering PP100–01.
Similarly, at the 10-h and 20-h venepuncture episodes,
study-specific blood samples will be collected.
Baseline assessments
Study-specific vital signs will be assessed at baseline (be-
tween 1 and 2 h after starting NAC) and again at 2.5, 10,
and 20 h after starting NAC (Fig. 3). The following vital
signs will be evaluated in a supine position after at least
5 min of rest: blood pressure (systolic and diastolic;
mmHg), heart rate (beats per minute), respiration rate
(per minute), pulse oximetry (%), temperature (°C), and
temperature route. Height (estimated) and weight (kg)
are collected at baseline. A baseline physical examination
will be completed assessing the cardiovascular, respira-
tory, and gastrointestinal systems. Any AEs and SAEs
identified during the examination will be recorded/re-
ported. Additional full physical examinations will be
completed if AE/SAEs were reported, requiring a more
thorough examination to be carried out. This will in-
clude assessment of local toxicity at the site of intraven-
ous administration. All women of childbearing potential
will be screened for pregnancy by urine or serum human
chorionic gonadotropin (hCG) test as part of the eligibil-
ity assessment. An electrocardiogram (ECG) will be per-
formed on resting patients at baseline, and at 2.5 h, 10 h,
and 20 h, and any clinically significant findings will be
recorded.
Randomisation
The allocation sequence for each dosing cohort will be
created using computer-generated random numbers,
Fig. 3 Diagram of the POP trial study design over a total of 22 h including blood sampling times and recording of adverse events. ECG
electrocardiogram, NAC N-acetylcysteine
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using blocking to ensure the required 6:2 ratio of NAC
+ PP100–01:NAC alone. The randomisation list is held
centrally at the Edinburgh Clinical Trials Unit (ECTU)
to conceal treatment allocations until these are imple-
mented via the ECTU secure web-based randomisation
system.
Treatment phase
Treatment starts with the first NAC bag of 100 mg/kg in
200 mL (“loading dose”) at time point ‘0’. After 2 h and
immediately prior to PP100–01 (if randomised to this
treatment), a study-specific blood sample will be col-
lected. PP100–01 treatment will be administered intra-
venously as a bolus infusion over 5 min at the dose
specified by the dosing cohort:
 Group A: PP100–01 (2 μmol/kg calmangafodipir)
after the “loading” dose of NAC
 Group B: PP100–01 (5 μmol/kg calmangafodipir)
after the “loading” dose of NAC
 Group C: PP100–01 (10 μmol/kg calmangafodipir)
after the “loading” dose of NAC
If the patient is randomised to the NAC-alone group
there is no intravenous injection 2 h after starting NAC.
In all patients, the 12-h NAC regimen will be continued
with the second dose: 200 mg/kg NAC diluted in 1000
mL delivered intravenously over 10 h. As per routine
clinical practice, there is one blood sample taken 2 h be-
fore the end of the second NAC bag (the 10-h time
point) and a second blood sample taken 10 h later (the
20-h time point) (Fig. 3).
Extension of NAC treatment
At the end of the 12-h NAC regimen the decision to
continue NAC will be made by assessment of the clinical
blood sample taken at the 10-h time point. NAC will be
continued at 200 mg/kg in 1000 mL intravenously over a
further 10 h if any of the following criteria are reached:
 the ALT has more than doubled since the admission
measurement, or
 the ALT is two times the upper limit of normal or
more, or
 the INR is greater than 1.3
 APAP concentration > 20 mg/mL
Adverse events
Adverse events/adverse reactions (AE/AR) are assessed
at baseline, and at 2 h, 2.5 h, 10 h, 20 h, and 22 h, and as
part of 7-, 30-, and 90-day follow-up. A full physical
examination will be carried out if AEs or SAEs are iden-
tified and this will be recorded on the electronic case re-
port form (e-CRF). All SAEs and suspected unexpected
serious adverse reactions (SUSARs) will be reported for
pharmacovigilance review within 24 h of identification.
All events are followed up until resolution or until no
longer medically indicated.
Follow-up
Patients will be followed up using their electronic re-
cords. The following data will be collected 7, 30, and 90
days after randomisation: re-presentation to hospital (for
any reason), re-presentation with liver injury, repeat
overdose, death, and transfer to liver transplantation
unit. Any AEs or SAEs identified will be recorded and
reported.
Primary objective
To determine the safety and tolerability of PP100–01
add-on treatment to the 12-h NAC treatment regimen
in patients treated for POD. The primary outcome is any
AEs or SAEs.
Secondary objectives
Secondary outcomes include:
 Clinical observations (pulse rate, blood pressure,
respiratory rate, pulse oximetry, temperature) and
haematological and clinical biochemistry parameters.
 Exploratory biomarkers in serum/plasma (miR-122,
K18, GLDH)
 Incidence of hepatotoxicity
 Duration of hospital stay (days)
 Re-presentation to hospital (for any reason), re-
presentation with liver injury, repeat overdose,
death, and transfer to liver transplantation unit, and
AEs and SAES up to 90 days.
Exploratory secondary outcomes will be collected to
improve the design of future clinical studies:
1) To determine the rate of occurrence of
hepatotoxicity (defined by raised biochemical
markers) in patients treated with PP100–01 and 12-
h NAC administration regimens.
2) To compare the incidence of anaphylactoid
reactions in the co-treatment and 12-h NAC regi-
mens in APAP poisoned patients.
3) To determine the occurrence of hepatotoxicity as
determined at the end of the 12-h NAC administra-
tion regimen.
4) To measure length of hospital stay in patients
receiving co-treatment and 12-h NAC treatment
regimens.
5) Proportion of patients with a 50% increase in ALT
after 10 h post-treatment with NAC, compared with
the admission value
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6) Proportion of patients with ALT > 100 at 10 h post-
treatment with NAC
7) Proportion of patients with INR > 1.3 at 10 h post-
treatment with NAC
8) Proportion of patients with APAP concentration >
20mg/mL
Independent Safety Data Monitoring Committee (SDMC)
An independent SDMC will be appointed to review ac-
cumulating AE data and patient safety. The SDMC will
evaluate the safety in relation to the PP100–01 dosing
step increase. The committee will give recommendations
on the continuation or termination of the study by de-
tection of any safety signals as early as possible in ac-
cordance with the SDMC Charter. The proposed
composition of the SDMC will be: independent hepatol-
ogist, independent statistician, independent clinical
pharmacologist/toxicologist. During the period of re-
cruitment into the study, interim analyses of in-hospital
mortality/morbidity and any other information that is
available on major outcome events (including SAEs be-
lieved to be due to treatment) will be supplied, in strict
confidence, to the Chairperson of the SDMC, along with
any other analyses that the committee may request.
All further patient enrolment will be paused pending
advice from the SDMC if one of the following stopping
rules have been met: 1) patient death, admission to a
critical care unit or admission to a liver transplantation
unit due to any reason; or 2) one SUSAR that definitely
or probably relates to either PP100–01 or NAC or both.
All SMDC data reviews will be documented and all
meetings will have written minutes, which will be filed
in the trial master file (TMF) upon completion of the
study.
Statistical analyses
Patients will be included in the full analysis population,
the primary population for analysis of efficacy, if they
have received any PP100–01 or NAC. Data will be ana-
lysed according to the randomised treatment group. The
stringent per-protocol population includes patients from
the full analysis population for whom the study protocol
has been followed without any major violations. The
population for safety analysis will be patients who have
received any PP100–01 or NAC. Data will be analysed
according to the treatment received (NAC plus PP100–
01, or NAC alone). Any patient who withdraws during
the treatment phase of the study will be included in the
safety population (AEs and laboratory parameters). Data
for all patients will be listed, and a list of withdrawn pa-
tients, with all reasons for withdrawal, will be given.
Data will also be listed for those patients who, after hav-
ing consented to participate, underwent baseline exami-
nations required for inclusion into the study but who,
because a criterion for exclusion was met or for other
reasons, were not included in the study.
With the clinical safety data that are available we do
not expect any SAEs, but we note that PP100–01 has
not been administered in POD patients treated with
NAC. We deem that six patients per group in this initial
dose escalation study will allow initial exploration of ef-
fects on biomarkers and potential dose-limiting toxicity.
A CONSORT diagram [14] depicting the flow of par-
ticipants and representing the number of patients split
by treatment group through the study will be reported.
Descriptive statistics will be used to report baseline char-
acteristics by treatment group and overall. Continuous
variables will be summarised by the mean, standard de-
viation, median, and minimum and maximum; categor-
ical variables will be summarised using the number and
percentage in each category. Log transformation will be
used where appropriate. Baseline characteristics will in-
clude participant details, overdose details, concomitant
medications during the preceding 30 days, physical
examination including cardiovascular, respiratory, and
gastrointestinal systems, vital signs, ECG, and clinical
bloods.
We will keep missing data to an absolute minimum,
but where there are missing data those records will be
removed from the analysis; if missing data rates are sub-
stantial the effect of this will be investigated using sensi-
tivity analyses.
Binary outcomes (including the primary outcome) will
be reported by treatment group and overall using the
proportion and exact 95% confidence interval. Binary
outcomes will be compared within dosing cohorts be-
tween the PP100–01 + NAC and the NAC-alone patients
using a difference in proportions and its exact 95% con-
fidence interval. Binary outcomes will be compared be-
tween each of the PP100–01 dosing groups (A, B, and
C) and the combined NAC-alone group in the same
way. Continuous outcomes will be reported by treatment
group and overall using the mean and 95% confidence
interval. Continuous outcomes will be compared within
dosing cohort between the PP100–01 + NAC and the
NAC-alone patients using the difference in means and
its 95% confidence interval. Continuous outcomes will
be compared between each of PP100–01 dose groups
(A, B, and C) and the combined NAC-alone group in
the same way. The continuous outcome analyses listed
above will be repeated using the change from baseline in
each continuous outcome.
The primary outcome
The number and percentage of patients experiencing an
AE will be summarised by treatment group and overall.
The primary analysis will be to report AE and SAE rates
by treatment group and overall using the method
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described above for binary outcomes. If the limited sam-
ple size or a small number of observed events leads to a
lack of interpretability of the formal analysis confidence
intervals, the analysis of the primary outcome will be re-
stricted to descriptive summaries only.
The number and percentage of patients experiencing
an AE will be summarised by subsets of AEs according
to the following criteria:
 SAEs
 AEs starting after the commencement of NAC
treatment and within 7 days of consent
 SAEs starting after the commencement of NAC
treatment and within 7 days of consent
 Intensity (mild/moderate/severe)
 Treatment given in response to AE (yes/no)
 Outcome (recovered/improved/unchanged/
deterioration/death)
 Relationship to NAC (unrelated/possibly related/
probably related/definitely related)
 Relationship to PP100–01 (unrelated/possibly
related/probably related/definitely related)
 Action taken with NAC (none/interrupted/stopped
entirely)
 Action taken with PP100–01 (none/interrupted/
stopped entirely)
 Unexpected with, and related to, NAC
 Unexpected with, and related to, PP100–01
 SUSAR, subcategorised into SUSAR to NAC,
SUSAR to PP100–01, and SUSAR to NAC and
PP100–01
Secondary outcomes
Safety
Vital signs (systolic blood pressure, diastolic blood pres-
sure, pulse, respiratory rate, temperature, oxygen satur-
ation) and haematology and clinical biochemistry
parameters (APAP level, PT, alkaline phosphatase, cre-
atinine, urea, WBC, potassium, bilirubin, haemoglobin,
MCV, sodium) will be summarised and analysed at their
measurement time points. The ECG result (normal/ab-
normal not clinically significant/abnormal clinically sig-
nificant) will be summarised by treatment group and
overall at 2.5, 10, and 20 h. The ECG summary results at
each of these time points will also be cross-tabulated
against the baseline ECG result, by treatment group and
overall. The proportion of anaphylactoid reactions re-
corded will be summarised by treatment group and
overall.
Efficacy
Hepatotoxicity will be assessed using ALT and INR. De-
scriptive summaries will be provided by treatment group
and overall at each measurement time point during the
treatment period (baseline, 10 h, 20 h). Change from
baseline to each of the 10- and 20-h time points will be
summarised by treatment group and overall for ALT and
INR. At each measurement time point during the treat-
ment period (baseline, 10 h, 20 h) ALT and INR will be
analysed by treatment group and overall using the mean
and 95% confidence interval. They will be compared
within each dosing cohort between the PP100–01 +
NAC and the NAC-alone patients using the difference
in means and its 95% confidence interval. The markers
will be compared between each of the PP100–01
2 μmol/kg, 5 μmol/kg, and 10 μmol/kg groups and the
combined NAC-alone group in the same way. We will
measure exploratory biomarkers with analysis as per
ALT.
Discussion
APAP is the most common drug taken in overdose in
the UK [15]. Hospitalisation due to APAP overdose
accounted for approximately 80,000 bed days in the UK
in 2005–2006. Current treatment involves use of NAC
in patients deemed at risk of potential liver damage. This
is given by intravenous infusion over a period of 21 h.
This regimen was designed in the 1970s, with a large
loading dose of the antidote administered followed by
two decreasing concentrations. The initial infusion is as-
sociated with adverse reactions, in particular nausea,
vomiting, and anaphylactoid reactions. The latter are
particularly troublesome and occur in up to 15% of pa-
tients treated. Therapy is discontinued and there is often
confusion as to whether therapy can be restarted in a
timely manner. Although highly effective in preventing
liver damage if given sufficiently early, further disadvan-
tages of the conventional intravenous NAC infusion
regimen are the high rates of adverse reactions and the
complexity of dosing and resulting high risk of medica-
tion errors.
The objective of this study is to develop a therapeutic
regimen for POD where a NAC 12-h regime is com-
bined with a SOD mimetic, PP100–01, to evaluate if re-
duction of the oxidative stress in the liver will be safe
and well tolerated. It would also allow preliminary data
to be collected on a new approach of giving NAC to-
gether with PP100–01 using the 12-h regimen, which in-
cluded a slower initial intravenous infusion over 2 h
instead of 1 h in the 21-h NAC regime.
The primary study outcome is therefore chosen to in-
form about the safety and tolerability of PP100–01
co-treatment with the NAC regime in patients with
POD. In addition, data on the incidence of adverse ef-
fects caused by the NAC plus PP100–01 regimen, and
changes in liver toxicity markers induced by
APAP-induced liver injury within this modified NAC
treatment will be obtained.
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If the combination of PP100–01 and NAC is tolerated,
then the next trial should focus on establishing a dose of
PP100–01 that has efficacy. To achieve this aim, sensi-
tive biomarkers of acute liver injury may be used as the
outcome measures. The current trial will provide valu-
able data regarding the variability of these biomarkers in
this population and may even demonstrate a ‘signal’ con-
sistent with efficacy of PP100–01 for the prevention of
APAP-induced liver injury.
In conclusion, this study is the first attempt to com-
bine a superoxide dismutase (SOD) mimetic, (P100–01),
co-treatment with a 12-h NAC regimen in patients with
POD. Developing and refining therapeutic regimens in
POD is important as the current 21-h regimen leads to
adverse reactions and may not be therapeutically optimal
or timely for lessening liver injury as a result. We antici-
pate this study will provide clinical trial evidence for the
safety and tolerability of PP100–01 when combined with
NAC treatment.
Trial status
This paper describes study protocol version V3 (28 June
2017). The trial opened on 5 June 2017. The first patient
was recruited on 8 June 2017. The expected end of re-
cruitment May 2018.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 121 kb)
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